Mark Anderson is a Cardiology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4050 W Memorial Rd Fl 3
Oklahoma City, OK 731208382
Telephone
405-608-3800Provider last certified this registry record 6 Jun 2022.
Clinical trials
- The Use of Impella RP Support System in Patients With Right Heart Failure
Sponsor: Abiomed Inc.
- RECOVER I Impella RECOVER LP/LD 5.0 Support System Safety and Feasibility Study
Sponsor: Abiomed Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
77%Beta blocker14.2%Metoprolol Succinate50%Carvedilol30%Metoprolol Tartrate13%Bisoprolol Fumarate5%Nebivolol Hcl2%Part D<11 patientsStatin12.4%Atorvastatin Calcium44%Rosuvastatin Calcium42%Pravastatin Sodium10%Simvastatin4%Part D≥125 patients+ 19 more classes in this area
Blood & clotting
17.5%Factor Xa inhibitor12.3%Eliquis80%Xarelto20%Part D≥136 patientsP2Y12 inhibitor3.8%Clopidogrel85%Brilinta15%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
5.5%Potassium supplement3.3%Potassium Chloride100%Part D≥67 patientsSGLT2 inhibitor1.4%Jardiance100%Part D≥16 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”